Update on taxanes in the first-line treatment of advanced non-small-cell lung cancer

被引：29
|
作者：
Socinski, M. A. [1 ]
机构：
[1] Univ Pittsburgh, Inst Canc, Pittsburgh, PA 15232 USA
来源：
CURRENT ONCOLOGY | 2014年 / 21卷 / 05期
关键词：
Docetaxel; elderly patients; nab-paclitaxel; paclitaxel; squamous cell carcinoma; PHASE-III TRIAL; PACLITAXEL PLUS CARBOPLATIN; ALBUMIN-BOUND PACLITAXEL; SOLVENT-BASED PACLITAXEL; SOUTHWEST-ONCOLOGY-GROUP; WEEKLY NAB-PACLITAXEL; ELDERLY-PATIENTS; RANDOMIZED-TRIAL; MULTICENTER TRIAL; COMBINATION CHEMOTHERAPY;
D O I：
10.3747/co.21.1997
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Based on demonstrated favourable risk-benefit profiles, taxanes remain a key component in the first-line standard of care for advanced non-small-cell lung cancer (NSCLC) and NSCLC subtypes. In 2012, a novel taxane, nab-paclitaxel (Abraxane: Celgene Corporation, Summit, NJ, U.S.A.), was approved, in combination with carboplatin, for the first-line treatment of locally advanced or metastatic NSCLC. The approval was granted because of demonstrated improved antitumour activity and tolerability compared with solvent-based paclitaxel-carboplatin in a phase III trial. This review focuses on the evolution of first-line taxane therapy for advanced NSCLC and the new options and advances in taxane therapy that might address unmet needs in advanced NSCLC.
引用
收藏
页码：E691 / E703
页数：13
相关论文
共 50 条
  • [31] How to make the best use of immunotherapy as first-line treatment of advanced/metastatic non-small-cell lung cancer
    Peters, S.
    Reck, M.
    Smit, E. F.
    Mok, T.
    Hellmann, M. D.
    ANNALS OF ONCOLOGY, 2019, 30 (06) : 884 - 896
  • [32] Taxanes as first-line therapy for advanced non-small cell lung cancer: A systematic review and practice guideline
    Chu, Q
    Vincent, M
    Logan, D
    Mackay, JA
    Evans, WK
    LUNG CANCER, 2005, 50 (03) : 355 - 374
  • [33] First-Line Treatment of Non-Small-Cell Lung Cancer (NSCLC) with Immune Checkpoint Inhibitors
    Olivier Bylicki
    Helene Barazzutti
    Nicolas Paleiron
    Jacques Margery
    Jean-Baptiste Assié
    Christos Chouaïd
    BioDrugs, 2019, 33 : 159 - 171
  • [34] Afatinib: A first-line treatment for selected patients with metastatic non-small-cell lung cancer
    Engle, Jeff
    Kolesar, Jill
    AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 2014, 71 (22) : 1933 - 1938
  • [35] Osimertinib as First-Line Treatment in EGFR-Mutated Non-Small-Cell Lung Cancer
    Popat, Sanjay
    NEW ENGLAND JOURNAL OF MEDICINE, 2018, 378 (02): : 192 - 193
  • [36] First-line management of advanced non-small-cell lung cancer: can we do better?
    Chouaid, Christos
    Monnet, Isabelle
    Auliac, Jean-Bernard
    TRANSLATIONAL LUNG CANCER RESEARCH, 2023, 12 (07) : 1643 - 1648
  • [37] Gefitinib as first-line, compassionate use therapy in patients with advanced non-small-cell lung cancer
    Argiris, A
    Mittal, N
    LUNG CANCER, 2004, 43 (03) : 317 - 322
  • [38] Bevacizumab as First-Line Therapy in Advanced Non-Small-Cell Lung Cancer A Brazilian Center Experience
    Fontes Jardim, Denis Leonardo
    Gagliato, Debora de Melo
    Ribeiro, Karina Braga
    Shimada, Andrea Kazumi
    Katz, Artur
    DRUGS IN R&D, 2012, 12 (04) : 207 - 216
  • [39] FIRST-LINE ERLOTINIB IN ELDERLY PATIENTS (PTS) WITH ADVANCED NON-SMALL-CELL LUNG CANCER (NSCLC)
    Merimsky, O.
    Cheng, A. C.
    Reck, M.
    Au, S. K.
    von Pawel, J.
    ANNALS OF ONCOLOGY, 2008, 19 : 101 - 102
  • [40] Immune checkpoint inhibitors as first-line and salvage therapy for advanced non-small-cell lung cancer
    Decatris, Marios P.
    O'Byrne, Kenneth J.
    FUTURE ONCOLOGY, 2016, 12 (15) : 1805 - 1822
12345